EP2073637A4 - Composés utiles pour traiter des maladies neurodégénératives - Google Patents

Composés utiles pour traiter des maladies neurodégénératives

Info

Publication number
EP2073637A4
EP2073637A4 EP06838050A EP06838050A EP2073637A4 EP 2073637 A4 EP2073637 A4 EP 2073637A4 EP 06838050 A EP06838050 A EP 06838050A EP 06838050 A EP06838050 A EP 06838050A EP 2073637 A4 EP2073637 A4 EP 2073637A4
Authority
EP
European Patent Office
Prior art keywords
compounds useful
neurodegenerative disorders
treating neurodegenerative
treating
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06838050A
Other languages
German (de)
English (en)
Other versions
EP2073637A1 (fr
Inventor
Mark A Findeis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Satori Pharmaceuticals Inc
Original Assignee
Satori Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satori Pharmaceuticals Inc filed Critical Satori Pharmaceuticals Inc
Publication of EP2073637A1 publication Critical patent/EP2073637A1/fr
Publication of EP2073637A4 publication Critical patent/EP2073637A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP06838050A 2006-11-20 2006-11-20 Composés utiles pour traiter des maladies neurodégénératives Withdrawn EP2073637A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/044880 WO2008063165A1 (fr) 2006-11-20 2006-11-20 Composés utiles pour traiter des maladies neurodégénératives

Publications (2)

Publication Number Publication Date
EP2073637A1 EP2073637A1 (fr) 2009-07-01
EP2073637A4 true EP2073637A4 (fr) 2011-12-28

Family

ID=39429980

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06838050A Withdrawn EP2073637A4 (fr) 2006-11-20 2006-11-20 Composés utiles pour traiter des maladies neurodégénératives

Country Status (10)

Country Link
EP (1) EP2073637A4 (fr)
JP (1) JP2010510309A (fr)
KR (1) KR20090087075A (fr)
CN (1) CN101610673A (fr)
AU (1) AU2006350960B2 (fr)
BR (1) BRPI0622138A2 (fr)
CA (1) CA2670276A1 (fr)
IL (1) IL198856A0 (fr)
MX (1) MX2009005351A (fr)
WO (1) WO2008063165A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US7990394B2 (en) 2007-05-25 2011-08-02 Google Inc. Viewing and navigating within panoramic images, and applications thereof
ES2567134T3 (es) 2009-08-05 2016-04-20 Infinity Pharmaceuticals, Inc. Transaminación enzimática de análogos de ciclopamina
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2016196928A1 (fr) 2015-06-04 2016-12-08 PellePharm, Inc. Formulations topiques pour l'administration de composés inhibiteurs du hérisson et leur utilisation
US10217283B2 (en) 2015-12-17 2019-02-26 Google Llc Navigation through multidimensional images spaces
US10245091B2 (en) 2015-12-30 2019-04-02 Exsomed Holding Company, Llc Dip fusion spike screw
CN107281206A (zh) * 2016-03-30 2017-10-24 南京惠宝生物医药有限公司 黑升麻苷在制备防治老年性痴呆药物中的应用
KR102120376B1 (ko) * 2018-05-28 2020-06-09 한국과학기술연구원 승마 추출물, 이의 분획물 또는 승마에서 유래된 화합물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물
CN109528738A (zh) * 2018-12-24 2019-03-29 陕西师范大学 甘草酸在制备促进髓鞘再生抑制神经炎症药物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023407A1 (fr) * 1999-09-29 2001-04-05 Phytopharm Plc Derives de sapogenine et leur utilisation dans le traitement de dysfonctionnement cognitif

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
EP1496913A4 (fr) * 2002-03-15 2007-10-31 Samaritan Pharmaceuticals Inc Compositions pharmaceutiques neuroprotectrices a base de spirostenol
CN101223185A (zh) * 2005-05-17 2008-07-16 萨托里医药公司 用于治疗神经变性障碍的化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023407A1 (fr) * 1999-09-29 2001-04-05 Phytopharm Plc Derives de sapogenine et leur utilisation dans le traitement de dysfonctionnement cognitif

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DE VIVAR A ET AL: "Triterpenes in Parthenium argentatum, structures of argtntatins C and D", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 29, no. 3, 1 January 1990 (1990-01-01), pages 915 - 918, XP026660019, ISSN: 0031-9422, [retrieved on 19900101], DOI: 10.1016/0031-9422(90)80045-I *
GANENKO, T.V. ET AL.: "Triterpenoids of Thalictrum foetidum and their biological activity", PROCEEDINGS OF THE FCES THIRD INTERNATIONAL CONFERENCE ON CHEMISTRY AND BIOTECHNOLOGY OF BIOLOGICALLY ACTIVE NATURAL PRODUCTS, 1985, pages 330 - 335, XP008144917 *
HERZ, W. ET AL.: "Cycloartanes form Lindheimera Texana", PHYTOCHEMISTRY, vol. 24, no. 11, 1985, pages 2645 - 2654, XP002662791 *
KUSANO, A. ET AL.: "Studies on the Constituents of cimicifuga Species. XIX. Eight New Glycosides from Cimicifuga simplex WORMSK.", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 44, no. 11, 1996, pages 2078 - 2085, XP002662794 *
KUSANO, A. ET AL.: "Studies on the Constituents of Cimicifuga Species. XVIII. Four New Xylosides from the Aerial Parts of Cimicifuga simplex WORMSK.", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 44, no. 1, 1996, pages 167 - 172, XP002662793 *
SAKURAI N ET AL: "Cancer preventive agents. Part 1: Chemopreventive potential of cimigenol, cimigenol-3,15-dione, and related compounds", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 4, 15 February 2005 (2005-02-15), pages 1403 - 1408, XP027637737, ISSN: 0968-0896, [retrieved on 20050215] *
SAKURAI, N. ET AL.: "Studies on the Chinese Crude Drug "Shoma."V. Structures of 24-O-Acetylhydroshengmanol Xyloside and 22-Hydroxycimigenol Xyloside", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 29, no. 4, 1981, pages 955 - 960, XP002662792 *
See also references of WO2008063165A1 *
TAKAHARA M ET AL: "Antimalarial Activity and Nucleoside Transport Inhibitory Activity of the Triterpenic Constituents of Cimicifuga spp", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 21, no. 8, 1 August 1998 (1998-08-01), pages 823 - 828, XP008073041, ISSN: 0918-6158 *

Also Published As

Publication number Publication date
KR20090087075A (ko) 2009-08-14
WO2008063165A1 (fr) 2008-05-29
BRPI0622138A2 (pt) 2011-12-27
IL198856A0 (en) 2010-02-17
JP2010510309A (ja) 2010-04-02
MX2009005351A (es) 2009-06-08
AU2006350960B2 (en) 2013-09-12
AU2006350960A1 (en) 2008-05-29
CN101610673A (zh) 2009-12-23
CA2670276A1 (fr) 2008-05-29
EP2073637A1 (fr) 2009-07-01

Similar Documents

Publication Publication Date Title
EP2083857A4 (fr) Procédés pour traiter des troubles en rapport avec le mica
HK1225620A1 (zh) 改善的神經再生的補充抑制
IL198856A0 (en) Compounds useful for treating neurodegenerative disorders
ZA200807015B (en) Dihydrothienopyrimidine for treating inflammatory disorders
AP2009004746A0 (en) Process for prepaiIrng diaminophenothiazinium compounds
ZA200809528B (en) Treatment for depressive disorders
AU2007288337A8 (en) Compounds for treating proliferative disorders
IL192692A0 (en) Compounds for the treatment of inflammatory disorders
IL198851A0 (en) Methods for treating hypercholesterolemia
ZA200900734B (en) Combination treatment for metabolic disorders
IL184456A0 (en) Dosage form for treating gastrointestinal disorders
ZA200809527B (en) Treatment for depressive disorders
IL209895A0 (en) Compounds for treating beta-amyloidoses
IL187439A0 (en) Compounds useful for treating neurodegenerative disorders
PL1993589T3 (pl) Sposoby leczenia chorób neurologicznych
ZA200801401B (en) Carbamate compounds for use in treating neurodegenerative disorders
PL1841433T3 (pl) Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego
EP2331097A4 (fr) Procédés de traitement de troubles du système nerveux central (cns)
IL194373A0 (en) Methods for treating kidney disorders
IL207906A0 (en) Treatment for ocular-related disorders
IL188127A0 (en) Methods for treating demyelination disorders
ZA200901672B (en) Compounds for treating proliferative disorders
ZA200807678B (en) Meridamycin analogues for the treatment of neurodegenerative disorders
ZA200903242B (en) Treatment for multiple myeloma
AP2010005225A0 (en) Process for treating sulphatecontaining effluent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090331

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SATORI PHARMACEUTICALS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C07J 71/00 20060101ALI20111107BHEP

Ipc: A61K 31/44 20060101ALI20111107BHEP

Ipc: A01N 43/42 20060101AFI20111107BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20111130

RIC1 Information provided on ipc code assigned before grant

Ipc: C07J 71/00 20060101ALI20111123BHEP

Ipc: A61K 31/44 20060101ALI20111123BHEP

Ipc: A01N 43/42 20060101AFI20111123BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140503